Literature DB >> 15211076

Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy.

A K Wallin1, L Gustafson, M Sjögren, C Wattmo, L Minthon.   

Abstract

Fifty consecutive outpatients with Alzheimer's disease (AD) received treatment with the cholinesterase inhibitor tacrine in an open longitudinal study. Assessments using Mini-Mental State Examination, Alzheimer's Disease Assessment Scale - cognitive subscale, and a global rating were made at baseline and at 6, 12, 24, 36, 48 and 60 months. Three outcome groups were characterized: responders, unchanged and deteriorated. Additional outcome measures were time until nursing home placement, and mortality rate. At 6 months -75%, at 12 months -42%, at 24 months -20%, and after that 10% of the patients still on medication had improved or remained stable. The mortality rate did not differ between the outcome groups. Response to tacrine treatment at 6 or 12 months was found to predict a prolonged time until nursing home placement. No predictors for a positive treatment response could be identified at baseline. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15211076     DOI: 10.1159/000079201

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  7 in total

1.  Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease.

Authors:  Kathy Dujardin; David Devos; Stéphane Duhem; Alain Destée; Rose-Marie Marié; Franck Durif; Lucette Lacomblez; Jacques Touchon; Pierre Pollak; Jean-Jacques Péré
Journal:  J Neurol       Date:  2006-09-22       Impact factor: 4.849

2.  The effect of donepezil treatment on cardiovascular mortality.

Authors:  K Sato; R Urbano; C Yu; F Yamasaki; T Sato; J Jordan; D Robertson; A Diedrich
Journal:  Clin Pharmacol Ther       Date:  2010-07-21       Impact factor: 6.875

3.  Carotid intima-media thickness as a predictor of response to cholinesterase inhibitors in Alzheimer's disease: an open-label trial.

Authors:  Pedro J Modrego; Consuelo Rios; José M Pérez Trullen; Maria J García-Gómara; José M Errea
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

4.  Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting.

Authors:  Asa K Wallin; Carina Wattmo; Lennart Minthon
Journal:  Neuropsychiatr Dis Treat       Date:  2011-09-30       Impact factor: 2.570

5.  Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial.

Authors:  Hossein Pakdaman; Ali Amini Harandi; Hamidreza Hatamian; Mojgan Tabatabae; Hosein Delavar Kasmaei; Amirhossein Ghassemi; Koroush Gharagozli; Farzad Ashrafi; Pardis Emami Naeini; Mehrnaz Tavakolian; Darush Shahin
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2015-03-07

6.  Factors associated with response to acetylcholinesterase inhibition in dementia: a cohort study from a secondary mental health care case register in london.

Authors:  Gayan Perera; Mizanur Khondoker; Matthew Broadbent; Gerome Breen; Robert Stewart
Journal:  PLoS One       Date:  2014-11-20       Impact factor: 3.240

7.  Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil.

Authors:  Cecilia M Persson; Asa K Wallin; Sten Levander; Lennart Minthon
Journal:  BMC Neurol       Date:  2009-02-10       Impact factor: 2.474

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.